-
2
-
-
84990525766
-
Proposed UK NHS prescribing list
-
Bonn D. Proposed UK NHS prescribing list [letter]. Lancet 1994; 344: 1495
-
(1994)
Lancet
, vol.344
, pp. 1495
-
-
Bonn, D.1
-
3
-
-
0028017281
-
Controlling the NHS drugs budget
-
Murfin D. Controlling the NHS drugs budget [letter]. BMJ 1994; 309: 957
-
(1994)
BMJ
, vol.309
, pp. 957
-
-
Murfin, D.1
-
4
-
-
0027096561
-
The economic implications of therapeutic conservatism
-
Griffin TD. The economic implications of therapeutic conservatism. Int Pharm J 1992; 6: 269-71
-
(1992)
Int Pharm J
, vol.6
, pp. 269-271
-
-
Griffin, T.D.1
-
5
-
-
0029042039
-
A UK national prescribing list?
-
Walley T. A UK national prescribing list? Pharmacoeconomics 1995; 7 (6): 471-4
-
(1995)
Pharmacoeconomics
, vol.7
, Issue.6
, pp. 471-474
-
-
Walley, T.1
-
6
-
-
0027267367
-
The economic implications of therapeutic conservatism
-
Griffin JP, Griffin TD. The economic implications of therapeutic conservatism. J R Coll Physicians Lond 1993; 27: 121-6
-
(1993)
J R Coll Physicians Lond
, vol.27
, pp. 121-126
-
-
Griffin, J.P.1
Griffin, T.D.2
-
7
-
-
0028912005
-
Therapeutic conservatism: More costly in the long term?
-
Griffin JP. Therapeutic conservatism: more costly in the long term? Pharmacoeconomics 1995; 7: 378-87
-
(1995)
Pharmacoeconomics
, vol.7
, pp. 378-387
-
-
Griffin, J.P.1
-
10
-
-
7344229573
-
Rationing and priorities in the NHS
-
January 5; Sect. A: (col. 3)
-
Neuberger J. Rationing and priorities in the NHS. The Times 1998 January 5; Sect. A: 21 (col. 3)
-
(1998)
The Times
, pp. 21
-
-
Neuberger, J.1
-
11
-
-
0040821125
-
Challenges for the National Health Service
-
Teeling-Smith G, editor. London: Office of Health Economics
-
Powell JE. Challenges for the National Health Service. In: Teeling-Smith G, editor. Innovative competition in medicine. London: Office of Health Economics, 1992: 97-107
-
(1992)
Innovative Competition in Medicine
, pp. 97-107
-
-
Powell, J.E.1
-
12
-
-
7344255964
-
Health care dilemmas
-
Teeling-Smith G, editor. London: Office of Health Economics
-
Jenkin P. Health care dilemmas. In: Teeling-Smith G, editor. Innovative competition in medicine. London: Office of Health Economics, 1992: 108
-
(1992)
Innovative Competition in Medicine
, pp. 108
-
-
Jenkin, P.1
-
13
-
-
7344237592
-
A new rationing debate begins in the UK
-
Dean M. A new rationing debate begins in the UK [abstract]. Lancet 1997; 35: 1305
-
(1997)
Lancet
, vol.35
, pp. 1305
-
-
Dean, M.1
-
14
-
-
0018601817
-
Constraints of drug regulation on the development of new drugs
-
Gross F. Constraints of drug regulation on the development of new drugs. Arch Toxicol 1979; 43: 9-17
-
(1979)
Arch Toxicol
, vol.43
, pp. 9-17
-
-
Gross, F.1
-
15
-
-
0019441928
-
A survey of products licensed in the United Kingdom from 1971-1981
-
Griffin JP, Diggle GE. A survey of products licensed in the United Kingdom from 1971-1981. Br J Clin Pharmacol 1981; 12: 453-63
-
(1981)
Br J Clin Pharmacol
, vol.12
, pp. 453-463
-
-
Griffin, J.P.1
Diggle, G.E.2
-
16
-
-
7344249196
-
The Schwartz view
-
Schwartz H. The Schwartz view. Scrip Mag 1997; Dec: 7-8
-
(1997)
Scrip Mag
, vol.DEC
, pp. 7-8
-
-
Schwartz, H.1
-
17
-
-
7344261492
-
The Schwartz view
-
Schwartz H. The Schwartz view. Scrip Mag 1998; Mar: 13-5
-
(1998)
Scrip Mag
, vol.MAR
, pp. 13-15
-
-
Schwartz, H.1
-
18
-
-
0031459202
-
Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system
-
Stahl MMS, Lindquist M, Petterson M, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997; 53: 163-9
-
(1997)
Eur J Clin Pharmacol
, vol.53
, pp. 163-169
-
-
Stahl, M.M.S.1
Lindquist, M.2
Petterson, M.3
-
19
-
-
0029801305
-
Interferon beta in multiple sclerosis: Clinical cost effectiveness falls at fiist hurdle
-
Richards RG. Interferon beta in multiple sclerosis: clinical cost effectiveness falls at fiist hurdle [letter]. BMJ 1996; 313: 1159
-
(1996)
BMJ
, vol.313
, pp. 1159
-
-
Richards, R.G.1
-
20
-
-
0029841601
-
Newly licensed drugs should be on probation until their value is demonstrated
-
Ferner RE. Newly licensed drugs should be on probation until their value is demonstrated. BMJ 1996; 313: 1157-8
-
(1996)
BMJ
, vol.313
, pp. 1157-1158
-
-
Ferner, R.E.1
-
21
-
-
0031965368
-
Interferon beta-1a for multiple sclerosis
-
Interferon beta-1a for multiple sclerosis. Drug Ther Bull 1998; 36: 7-8
-
(1998)
Drug Ther Bull
, vol.36
, pp. 7-8
-
-
-
22
-
-
0032499366
-
Interferon beta produces only small benefits in multiple sclerosis
-
McKee L. Interferon beta produces only small benefits in multiple sclerosis [abstract]. BMJ 1998; 316: 1410
-
(1998)
BMJ
, vol.316
, pp. 1410
-
-
McKee, L.1
-
23
-
-
0030714579
-
Too soon to market: Doctors and patients need more information before drugs enter routine use
-
Dent THS, Hauke S. Too soon to market: doctors and patients need more information before drugs enter routine use. BMJ 1997; 315: 1248-9
-
(1997)
BMJ
, vol.315
, pp. 1248-1249
-
-
Dent, T.H.S.1
Hauke, S.2
-
24
-
-
85007670693
-
Too soon to market: Statistical aspects of research done outside the pharmaceutical industry could be improved
-
Senn S. Too soon to market: statistical aspects of research done outside the pharmaceutical industry could be improved [letter]. BMJ 1998; 316: 228
-
(1998)
BMJ
, vol.316
, pp. 228
-
-
Senn, S.1
-
25
-
-
85007670693
-
Too soon to market: Data available before products launched are poor
-
Clark W, Fisher M, Misson J. Too soon to market: data available before products launched are poor. BMJ 1998; 316: 228-9
-
(1998)
BMJ
, vol.316
, pp. 228-229
-
-
Clark, W.1
Fisher, M.2
Misson, J.3
-
26
-
-
0032539309
-
Too soon to market: Problems apply to introduction of new prosthetic implants as well as drugs
-
Sochart DH. Too soon to market: problems apply to introduction of new prosthetic implants as well as drugs [letter]. BMJ 1998; 316: 229
-
(1998)
BMJ
, vol.316
, pp. 229
-
-
Sochart, D.H.1
-
27
-
-
0032539274
-
Too soon to market: Problem is acute in dermatology
-
Williams HC. Too soon to market: problem is acute in dermatology [letter]. BMJ 1998; 316: 229
-
(1998)
BMJ
, vol.316
, pp. 229
-
-
Williams, H.C.1
-
28
-
-
0032539304
-
Too soon to market: Problem does not just occur with British markets
-
Wolff F. Too soon to market: problem does not just occur with British markets [letter]. BMJ 1998; 316: 229
-
(1998)
BMJ
, vol.316
, pp. 229
-
-
Wolff, F.1
-
29
-
-
33646836642
-
Drug trials in epilepsy: New drugs have been poorly assessed
-
Mignot G. Drug trials in epilepsy: new drugs have been poorly assessed [letter]. BMJ 1996; 313: 1158
-
(1996)
BMJ
, vol.313
, pp. 1158
-
-
Mignot, G.1
-
30
-
-
0030577195
-
Long term use of lamotrigine and vigabatrin in severe refractory epilepsy: Audit of outcome
-
Walker MC, Li LM, Sander WAS. Long term use of lamotrigine and vigabatrin in severe refractory epilepsy: audit of outcome. BMJ 1996; 313: 1184-5
-
(1996)
BMJ
, vol.313
, pp. 1184-1185
-
-
Walker, M.C.1
Li, L.M.2
Sander, W.A.S.3
-
31
-
-
0029822510
-
New antiepleptic drugs: A systematic review of their efficacy and tolerability
-
Marson AG, Kadir ZA, Chadwick DW. New antiepleptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 313: 1169-74
-
(1996)
BMJ
, vol.313
, pp. 1169-1174
-
-
Marson, A.G.1
Kadir, Z.A.2
Chadwick, D.W.3
-
32
-
-
0030707474
-
Economic evaluation of pharmaceuticals: What are reasonable standards for clinical evidence - The Australian experience
-
Hill S, Henry D, Pekarsky B, et al. Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence - the Australian experience. Br J Clin Pharmacol 1997; 44: 421-5
-
(1997)
Br J Clin Pharmacol
, vol.44
, pp. 421-425
-
-
Hill, S.1
Henry, D.2
Pekarsky, B.3
-
33
-
-
7344231286
-
A clinical benefit must not be confused with cost benefit
-
Rawlins M, Breckenridge A. A clinical benefit must not be confused with cost benefit [letter]. BMJ 1998; 316: 400
-
(1998)
BMJ
, vol.316
, pp. 400
-
-
Rawlins, M.1
Breckenridge, A.2
-
35
-
-
0030747752
-
Regulating the pharmaceutical industry
-
Maynard A, Bloor K. Regulating the pharmaceutical industry. BMJ 1947; 315: 200-1
-
(1947)
BMJ
, vol.315
, pp. 200-201
-
-
Maynard, A.1
Bloor, K.2
-
37
-
-
0032539373
-
Regulating the pharmaceutical industry: General public does not support value system inherent in cost-effectiveness analyses
-
Furniss J, Zammit-Lucia J, Johnson N. Regulating the pharmaceutical industry: general public does not support value system inherent in cost-effectiveness analyses [letter]. BMJ 1998; 316: 226
-
(1998)
BMJ
, vol.316
, pp. 226
-
-
Furniss, J.1
Zammit-Lucia, J.2
Johnson, N.3
-
38
-
-
85044700943
-
Regulating the pharmaceutical industry: Authors seem to have misunderstood the pharmaceutical price regulation scheme
-
Read P. Regulating the pharmaceutical industry: authors seem to have misunderstood the pharmaceutical price regulation scheme [letter]. BMJ 1998; 316: 226
-
(1998)
BMJ
, vol.316
, pp. 226
-
-
Read, P.1
-
39
-
-
0032539319
-
Regulating the pharmaceutical industry: Having rationing rules for new pharmaceuticals but not other treatments is senseless
-
Towse A. Regulating the pharmaceutical industry: having rationing rules for new pharmaceuticals but not other treatments is senseless [letter]. BMJ 1998; 316: 227
-
(1998)
BMJ
, vol.316
, pp. 227
-
-
Towse, A.1
-
40
-
-
0032539303
-
Regulating the pharmaceutical industry: Regulation may no longer be necessary
-
Rowlatt P. Regulating the pharmaceutical industry: regulation may no longer be necessary [letter]. BMJ 1998; 316: 227
-
(1998)
BMJ
, vol.316
, pp. 227
-
-
Rowlatt, P.1
-
41
-
-
0032539282
-
Regulating the pharmaceutical industry: Further controls would discourage companies investing in research
-
Lance S. Regulating the pharmaceutical industry: further controls would discourage companies investing in research [letter]. BMJ 1998; 316: 227-8
-
(1998)
BMJ
, vol.316
, pp. 227-228
-
-
Lance, S.1
-
42
-
-
0028889889
-
Support for trials of promising medications through the Pharmaceutical Benefits Scheme
-
Glasziou PP. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. Med J Aust 1995; 162: 33-6
-
(1995)
Med J Aust
, vol.162
, pp. 33-36
-
-
Glasziou, P.P.1
-
43
-
-
0032539323
-
Regulating the pharmaceutical industry: Australian scheme has disadvantages
-
Clear PR, Grobler M. Regulating the pharmaceutical industry: Australian scheme has disadvantages [letter]. BMJ 1998; 316: 227
-
(1998)
BMJ
, vol.316
, pp. 227
-
-
Clear, P.R.1
Grobler, M.2
-
44
-
-
7344258516
-
The pros and cons of the PPRS
-
Griffin JP. The pros and cons of the PPRS. Scrip Mag 1997; Oct: 11-3
-
(1997)
Scrip Mag
, vol.OCT
, pp. 11-13
-
-
Griffin, J.P.1
-
45
-
-
84887256630
-
Risk assessment: A changing perspective
-
Mann RD, editor. Carnforth (Lancashire): Parthenon Publishing
-
Griffin JP. Risk assessment: a changing perspective. In: Mann RD, editor. Risk and consent to risk in medicine. Carnforth (Lancashire): Parthenon Publishing, 1989: 133-53
-
(1989)
Risk and Consent to Risk in Medicine
, pp. 133-153
-
-
Griffin, J.P.1
-
46
-
-
0003665913
-
-
London: Publ Stationary Office Ltd.
-
Department of Health. The new NHS: modern dependable CM3807. London: Publ Stationary Office Ltd., 1997
-
(1997)
The New NHS: Modern Dependable CM3807
-
-
-
47
-
-
7344221693
-
Reimbursement for Viagra unlikely in Germany
-
Reimbursement for Viagra unlikely in Germany. Eur Drug Device Rep 1998; 8 (13): 5
-
(1998)
Eur Drug Device Rep
, vol.8
, Issue.13
, pp. 5
-
-
|